Transcept Sees Road To Intermezzo Approval Without More Driving Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
The company says FDA "generally agreed" with a proposal for dosing reductions and labeling changes for the middle-of-the-night insomnia drug, which has received two "complete response" letters.
You may also be interested in...
Second Intermezzo "Complete Response" Threatens Transcept's Partnership Payments
If approval is not gained by Sept. 23, partner Purdue Pharma will not have to make a $30 million milestone payment.
Transcept's Intermezzo Yields To FDA Concerns Over Residual Side Effects
Transcept's low-dose zolpidem for middle-of-the-night awakenings may need additional studies, including driving tests.
Transcept Hopes To Sleep Well Thanks To Insomnia Pill Deal With Purdue Pharma
The drug maker hopes to market the first medication for people who wake in the middle of the night.